Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1

被引：0

作者：

Hou, Jian ^{[1
]}

Jin, Jie ^{[2
]}

Xu, Yan ^{[3
]}

Wu, Depei ^{[4
]}

Ke, Xiaoyan ^{[5
]}

Daobin, Zhou ^{[6
]}

Lu, Jin ^{[7
]}

Du, Xin ^{[8
]}

Chen, Xiequn ^{[9
]}

Li, Junmin ^{[10
]}

Liu, Jing ^{[11
]}

Gupta, Neeraj ^{[12
]}

Hanley, Michael ^{[12
]}

Li, Hongmei ^{[12
]}

Hua, Zhaowei ^{[12
]}

Wang, Bingxia ^{[12
]}

Zhang, Xiaoquan ^{[12
]}

Wang, Hui ^{[12
]}

van de Velde, Helgi ^{[12
]}

Richardson, Paul ^{[13
]}

Moreau, Philippe ^{[14
]}

机构：

[1] Second Mil Med Univ, ChangZheng Hosp, Shanghai, Peoples R China

[2] Zhe Jiang Med Univ, Hosp Affiliated 1, Hangzhou, Zhejiang, Peoples R China

[3] Chinese Acad Med Sci, Inst Hematol & Blood Dis, Tianjin, Peoples R China

[4] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China

[5] Beijing Med Univ, Affiliated Hosp 3, Beijing, Peoples R China

[6] Peking Univ, Med Coll Hosp, Beijing, Peoples R China

[7] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[8] Guangdong Prov Peoples Hosp, Guangzhou, Guangdong, Peoples R China

[9] Fourth Mil Med Univ, Xijing Hosp, Xian, Peoples R China

[10] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai, Peoples R China

[11] Hosp Xiang Ya Med Univ, Hosp 3, Changsha, Hunan, Peoples R China

[12] Millennium Pharmaceut Inc, Cambridge, MA USA

[13] Dana Farber Canc Inst, Boston, MA 02115 USA

[14] CHU Nantes, Univ Hosp Hotel Dieu HME, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期

关键词：

D O I：

10.1016/j.clml.2017.03.121

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS-119

引用

页码：E67 / E67

页数：1

共 50 条

[1] IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): CHINA CONTINUATION OF TOURMALINE-MM1
Hou, J.
Jin, J.
Xu, Y.
Wu, D.
Ke, X.
Daobin, Z.
Lu, J.
Du, X.
Chen, X.
Li, J.
Liu, J.
Wang, B.
Zhang, X.
Wang, H.
van de Velde, H.
Richardson, P.
Moreau, P.
[J]. HAEMATOLOGICA, 2016, 101 : 540 - 540
[2] Ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM): China continuation of TOURMALINE-MM1.
Hou, Jian
Jin, Jie
Xu, Yan
Wu, Depei
Ke, Xiaoyan
Zhou Daobin
Lou, Jin
Du, Xin
Chen, Xiequn
Li, Junmin
Liu, Jing
Wang, Bingxia
Zhang, Xiaoquan
Wang, Hui
Van De Velde, Helgi
Richardson, Paul G.
Moreau, Philippe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[3] Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies
Fu, Weijun
Lu, Jin
Jin, Jie
Xu, Yan
Wu, Depei
Zhou, Dao-bin
Ke, Xiaoyan
Du, Xin
Chen, Xiequn
Chng, Wee Joo
Kim, Kihyun
Li, Junmin
Lee, Jae Hoon
Liu, Jing
Goh, Yeow Tee
Wu, Kwang-Wei
Wang, Hui
Liu, Guohui
Skacel, Tomas
Wan, Hui
Berg, Deborah
[J]. BLOOD, 2018, 132
[4] Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.
Mateos, Maria-Victoria
Masszi, Tamas
Grzasko, Norbert
Hansson, Markus
Sandhu, Irwindeep
Pour, Ludek
Viterbo, Luisa
Jackson, Sharon R.
Stoppa, Anne-Marie
Gimsing, Peter
Hamadani, Mehdi
Borsaru, Gabriela
Berg, Deborah
Lin, Jianchang
Van De Velde, Helgi
Richardson, Paul G.
Moreau, Philippe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] EFFICACY AND SAFETY OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: IMPACT OF PRIOR THERAPY IN THE PHASE 3 TOURMALINE-MM1 STUDY
Mateos, M. V.
Masszi, T.
Grzasko, N.
Hansson, M.
Sandhu, I.
Pour, L.
Viterbo, L.
Jackson, S.
Stoppa, A. M.
Gimsing, P.
Hamadani, M.
Borsaru, G.
Berg, D.
Lin, J.
van de Velde, H.
Richardson, P.
Moreau, P.
[J]. HAEMATOLOGICA, 2016, 101 : 527 - 527
[6] Efficacy and safety of ixazomib plus lenalidomidedexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.
Richardson, Paul G.
Avet-Loiseau, Herve
Palumbo, Antonio
Viterbo, Luisa
Nagler, Arnon
Ganly, Peter
Ben Yehuda, Dina
Miguel, Jesus San
Rajkumar, S. Vincent
Pour, Ludek
Langer, Christian
Bahlis, Nizar J.
Pluta, Andrzej
Masszi, Tamas
Berg, Deborah
Lin, Jianchang
Van De Velde, Helgi
Esseltine, Dixie-Lee
di Baccot, Alessandra
Moreau, Philippe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] IMPACT OF CYTOGENETIC RISK STATUS ON EFFICACY AND SAFETY OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN THE GLOBAL TOURMALINE-MM1 STUDY
Avet-Loiseau, H.
Bahlis, N.
Chng, W. J.
Masszi, T.
Viterbo, L.
Pour, L.
Ganly, P.
Palumbo, A.
Cavo, M.
Langer, C.
Pluta, A.
Nagler, A.
Kumar, S.
Ben-Yehuda, D.
Rajkumar, S. V.
Miguel, J. San
Berg, D.
Lin, J.
van de Velde, H.
Badola, S.
Gao, F.
Zhange, J.
Shen, L.
Li, B.
Esseltine, D. L.
di Bacco, A.
Moreau, P.
Richardson, P.
[J]. HAEMATOLOGICA, 2016, 101 : 80 - 80
[8] HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Hari, P.
Lin, H. M.
Zhu, Y.
Berg, D.
Richardson, P.
Moreau, P.
[J]. HAEMATOLOGICA, 2017, 102 : 297 - 298
[9] PATIENT-REPORTED QUALITY OF LIFE WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN THE GLOBAL, PLACEBO-CONTROLLED TOURMALINE-MM1 STUDY
Leleu, X.
Masszi, T.
Bahlis, N. J.
Viterbo, L.
Baker, B.
Gimsing, P.
Maisnar, V.
Samoilova, O.
Rosinol, L.
Langer, C.
Song, K.
Izumi, T.
Cleeland, C.
Berg, D.
Lin, H. M.
Zhu, Y.
Skacel, T.
Jhaveri, M.
Seal, B.
Moreau, P.
Richardson, P. G.
[J]. HAEMATOLOGICA, 2016, 101 : 261 - 261
[10] Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/ Refractory Multiple Myeloma (RRMM)
Di Bacco, Alessandra
Bahlis, Nizar J.
Munshi, Nikhil C.
Avet-Loiseau, Herve
Masszi, Tamas
Viterbo, Luisa
Pour, Ludek
Ganly, Peter
Cavo, Michele
Langer, Christian
Kumar, Shaji
Rajkumar, S. Vincent
Berg, Deborah
Lin, Jianchang
Li, Bin
Badola, Sunita
Shen, Lei
Zhang, Jacob
Wang, Ling
Esseltine, Dixie-Lee
Luptakova, Katarina
de Velde, Helgi van
Richardson, Paul G.
Moreau, Philippe
[J]. BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →